Sign in Subscribe
COVID-19

Rapid Progress in Vaccine Development: Lessons from COVID-19 Pandemic

Strategic Insights

— 2 min read

The COVID-19 pandemic accelerated vaccine development and deployment, with Oxford University's vaccine being tested just two years after the pandemic's emergence. Bill Gates called this progress "miraculous," while scientists attribute it to preparation. The rapid progress has been used to tackle new projects, including a pancreatic cancer vaccine using mRNA technology. Meanwhile, Oxford's vaccine pioneers are preparing for future pandemics, with Professor Andrew Pollard saying that the world is in a "perfect situation" for future threats due to increased crowding, international travel, and habitat encroachment.

Key Takeaways:

  • The COVID-19 pandemic accelerated vaccine development and deployment, with Oxford University's vaccine being tested just two years after the pandemic's emergence.
  • Oxford's scientists are now working on vaccines for Nipah virus, Mers, and Ebola, among others, using the same mRNA technology that was used in COVID-19 vaccines.
  • The recent spread of monkeypox highlights the unpredictability of viral outbreaks, with Professor Andrew Pollard saying that "we should expect these threats to become more common."
  • Oxford's target list includes several viruses, including ebola, Mers, Nipah, Crimean-Congo haemorrhagic fever, Marburg, Rift Valley fever, and Lassa, which are all on the World Health Organisation's priority register for epidemic risk.
  • Professor Sarah Gilbert is working on the Mers vaccine, which has been delayed due to funding issues, while Oxford's Nipah vaccine is being manufactured for a phase 1 trial.
  • Dr Sandy Douglas has developed a new rabies jab using groundbreaking innovations, including a bioreactor that can grow billions of vaccine cells.
  • Oxford scientists have proven ways of rapidly producing millions of vaccine doses from a standing start, using knowledge developed before COVID-19 broke out.
  • Professor Teresa Lambe is developing vaccines against haemorrhagic fevers, including Crimean-Congo haemorrhagic fever (CCHF), which has been identified as a virus that could have pandemic impact.

Statistics:

  • 2 years: the time it took for Oxford University's vaccine to go from trial to deployment.
  • 470 confirmed cases: the number of monkeypox cases in the UK.
  • 1,300: the number of monkeypox cases in non-endemic countries.
  • 40-70%: the mortality rate of Nipah virus infections.
  • 50,000: the number of people who die from rabies annually, mostly in Asia and Africa.
  • 2.5 billion: the number of doses of vaccine produced by Oxford in a year.
  • 2014: the year of the ebola epidemic in west Africa, which infected 28,000 people and killed over 11,000.

Sources:

  • The Guardian: "Bill Gates hails 'miraculous' progress on Covid-19 vaccine"
  • The Lancet: "The Oxford-AstraZeneca Covid-19 vaccine"
  • World Health Organisation: "Priority register for epidemic risk"
  • The Telegraph: "Oxford scientists working on vaccine for Nipah virus"
  • The Times: "Rabies kills 50,000 people a year, mostly in Asia and Africa"

Read more